Non-Small Cell Lung Cancer Market is Anticipated to Witness High Growth

The rising prevalence of non-small cell lung cancer (NSCLC) is anticipated to drive the growth of the global non-small cell lung cancer market. NSCLC accounts for approximately 85% of all lung cancer cases. It is characterized by heterogeneous tumors with distinct patterns of metastasis and response to treatment. The drugs used in the treatment of NSCLC are chemotherapy drugs, targeted therapy drugs, and immunotherapy drugs. Targeted therapy drugs are expected to gain more popularity as they work by blocking the growth and spread of cancer cells by interfering with specific targeted molecules involved in tumor growth and progression.

Key Takeaways
Key players operating in the Non-Small Cell Lung Cancer Market Demand are AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company. The non-small cell lung cancer market is consolidated with large international market players dominating the scene. However, increased R&D in targeted therapies, immunotherapy drugs and molecular diagnostic tests is expect to create opportunities for new players in the market.

Major players are investing in strengthening their positions in emerging markets through expansion of manufacturing and distribution facilities. For instance, AstraZeneca recently expanded its manufacturing facility in Gaithersburg, Maryland to increase the production of Tagrisso (osimertinib), its leading treatment for a type of metastatic non-small cell lung cancer associated with specific epidermal growth factor receptor (EGFR) mutations.

Market Drivers and Restraints
Rising smoking rates is one of the key drivers of the non-small cell lung cancer market. Cigarette smoking is the prime cause of lung cancer and causes around 80-90% of lung cancer deaths. Furthermore, people who smoke are at least ten times more likely to develop lung cancer than non-smokers. Tobacco smoke contains over 7,000 chemicals, of which at least 250 are known to be harmful and around 69 can cause cancer. However, high treatment costs associated with NSCLC therapies poses a major challenge to market growth. Targeted therapy and immunotherapy drugs are highly priced owing to their premium development costs. This hinders their adoption, specifically in price sensitive developing markets.

Segment Analysis
The Non-Small Cell Lung Cancer Market is segmented into squamous cell carcinoma and non-squamous cell carcinoma. Squamous cell carcinoma holds the largest share in the market currently due to its greater prevalence rate. This segment is expected to retain its dominance over the forecast period owing to increasing risk factors like smoking which is a major cause of squamous cell carcinoma.

Global Analysis
North America holds the largest share in the non-small cell lung cancer market currently. This is attributed to increasing prevalence of lung cancer, supportive government programs for cancer treatment and availability of advanced treatment procedures in the region. Asia Pacific is projected to grow at the fastest rate during the forecast period. Rising geriatric population, increasing smoking rates and growing healthcare expenditure are some of the factors fueling the growth of non-small cell lung cancer market in Asia Pacific.

Get more insights on Non-Small Cell Lung Cancer Market